September 24, 2024 by Krishna Ramanujan, Cornell University A classic psychedelic, similar to LSD, psilocybin and mescalin, was found to activate a cell type in the brain that silences other neighboring neurons, a result that provides insight into how such drugs reduce anxiety, according to a new study. The findings show the psychedelic DOI (2,5-dimethoxy-4-iodoamphetamine)...
Tag: <span>Psychedelics</span>
Post
Could psychedelics aid in the treatment of OCD?
by Eric W. Dolan in Mental Health, Psychedelic Drugs Scientists have begun to investigate whether psychedelic substances could aid in the treatment of obsessive-compulsive disorder. A preliminary study, published in Scientific Reports, has found that more than 30% of individuals with OCD who consumed these substances reported positive effects lasting for more than three months. OCD is...
Post
Exploring what happens in the brain under the influence of psychedelics, while meditating and during hypnosis
by Ingrid Fadelli, Medical Xpress Psilocybin, LSD, hypnosis, and meditation each induce distinct changes in rs-fcMRI. Paired t-tests were conducted to compare intervention vs. control for each ASC intervention method: (A) psilocybin (N=23), (B) LSD (N=25), (C) hypnosis (N=30), and (D) meditation (N=29). (A-D) Center shows the cluster pairs that survived connection thresholding (p<0.05 TFCE...
Post
As psychedelics near approval, there’s no consensus on how they work
By Olivia Goldhill July 3, 2023 ADOBE DENVER — The founder of Field Trip, a chain of shuttered ketamine clinics currently facing insolvency, put forward an unexpected theory of how psychedelics work to treat depression last month. “The truth is, almost all of the effect of psychedelic-assisted therapy could be placebo,” said Ronan Levy, speaking at a five-day conference...
Post
Psychedelics show promise in treating mental illness
by Tonia Moxley, Virginia Tech Doctoral student Bohan Zhu works in the lab of Chang Lu on projects that could lead to new treatments for depression, anxiety, and substance use disorder. Credit: Tonia Moxley for Virginia Tech One in five U.S. adults will experience a mental illness in their lifetime, according to the National Alliance of...
Post
LSD “off-switch” developed by psychedelic pharmaceutical company
By Rich Haridy Psychedelic pharmaceutical company MindMed has announced the development of a novel compound designed to stop the effects of an LSD experience. The compound is claimed to function as an “off-switch” for LSD, allowing clinicians a way to make psychedelic therapy sessions safer if patients become uncomfortable. The new announcement comes several weeks...
Post
Psychedelics to treat mental illness? Australian researchers are giving it a go
An estimated one in ten Australians were taking antidepressants in 2015. That’s double the number using them in 2000, and the second-highest rate of antidepressant use among all OECD countries. Yet some studies have found antidepressants might be no more effective than placebo. Not only does this mean many Australians aren’t experiencing relief from their psychological distress, but some may also be...